title: Smaller reduction in 3D breast density associated with subsequent cancer recurrence in patients with breast cancer receiving adjuvant tamoxifen therapy.
abstract: OBJECTIVE
  The purpose of this study was to retrospectively investigate whether 3D breast density changes measured using MRI were associated with recurrent cancer in patients with breast cancer who received adjuvant tamoxifen.
  
  
  METHODS
  A search of the breast MRI database (2007-2008) revealed a dataset that included 80 women (mean age, 44 years; range, 27-68 years) with breast cancer who underwent breast-conserving surgery, adjuvant tamoxifen treatment, and breast MRI before and after tamoxifen. The following clinicopathologic variables were collected: age, body mass index, menopausal status, family history, tumor stage, tumor grade, hormonal receptor status, and adjuvant chemotherapy status. MRI variables (total breast volume, fibro-glandular volume, and breast density) were measured for the contralateral untreated breast before and after tamoxifen treatment, and the percentage changes were recorded. A multivariate logistic regression analysis was performed to identify independent factors that were associated with cancer recurrence.
  
  
  RESULTS
  Overall, 12 (15%) of the 80 women developed recurrence. No recurrent cancers were found in the remaining 68 patients (85%) at a median follow-up of 48 months (range, 37-60 months). Percentage reduction of breast density after tamoxifen was the only independent factor associated with recurrence (adjusted odds ratio [OR] = 0.848, 95% CI = 0.769-0.935, and p = 0.001 for observer 1; adjusted OR = 0.957, 95% CI = 0.919-0.996, and p = 0.032 for observer 2) in the multivariate analysis.
  
  
  CONCLUSIONS
  Three-dimensional breast density changes measured using MRI during tamoxifen treatment were an independent factor associated with cancer recurrence in patients with breast cancer who received adjuvant tamoxifen.
authors.affiliation: 1 Department of Radiology, Seoul National University College of Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 110-744, Republic of Korea.
authors.forename: Jin You
authors.initials: JY
authors.lastname: Kim
authors.forename: Nariya
authors.initials: N
authors.lastname: Cho
authors.forename: Joseph Xavier
authors.initials: JX
authors.lastname: Jeyanth
authors.forename: Won Hwa
authors.initials: WH
authors.lastname: Kim
authors.forename: Su Hyun
authors.initials: SH
authors.lastname: Lee
authors.forename: Hye Mi
authors.initials: HM
authors.lastname: Gweon
authors.forename: Woo Kyung
authors.initials: WK
authors.lastname: Moon
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D015992:Body Mass Index; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D021621:Imaging, Three-Dimensional; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008875:Middle Aged; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D009367:Neoplasm Staging; D012189:Retrospective Studies; D013629:Tamoxifen / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen